Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manja Idorn

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Advanced Healthcare Materials|November 4, 2021
Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion BioreactorMaria Rafaeva, Edward R Horton, Adina R D Jensen, et al.
Cancer Research|June 29, 2017
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ SignalingMarco Donia, Katja Harbst, Marit van Buuren, et al.
The Journal of Experimental Medicine|October 9, 2025
Role for NF-κB in herpes encephalitis pathology in mice genocopying an inborn error of IRF3-IFN immunityManja Idorn, Xiangning Ding, Stefanie Fruhwürth, et al.
Nature|July 24, 2024
TMEFF1 is a neuron-specific restriction factor for herpes simplex virusYao Dai, Manja Idorn, Manutea C Serrero, et al.
The EMBO Journal|February 18, 2022
TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infectionRenée M van der Sluis, Lamin B Cham, Albert Gris-Oliver, et al.
The Lancet. Microbe|January 21, 2023
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2Merel J Smit, Adam F Sander, Maud B P A Ariaans, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 8, 2022
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screenZaid Taha, Rozanne Arulanandam, Glib Maznyi, et al.
ACS Infectious Diseases|October 18, 2021
Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of ConcernMadalina Elena Carter-Timofte, Rozanne Arulanandam, Naziia Kurmasheva, et al.
Nature Communications|October 22, 2020
Author Correction: SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarateDavid Olagnier, Ensieh Farahani, Jacob Thyrsted, et al.
Nature Communications|October 3, 2020
SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarateDavid Olagnier, Ensieh Farahani, Jacob Thyrsted, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Advanced Healthcare Materials|November 4, 2021
Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion BioreactorMaria Rafaeva, Edward R Horton, Adina R D Jensen, et al.
Cancer Research|June 29, 2017
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ SignalingMarco Donia, Katja Harbst, Marit van Buuren, et al.
The Journal of Experimental Medicine|October 9, 2025
Role for NF-κB in herpes encephalitis pathology in mice genocopying an inborn error of IRF3-IFN immunityManja Idorn, Xiangning Ding, Stefanie Fruhwürth, et al.
Nature|July 24, 2024
TMEFF1 is a neuron-specific restriction factor for herpes simplex virusYao Dai, Manja Idorn, Manutea C Serrero, et al.
The EMBO Journal|February 18, 2022
TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infectionRenée M van der Sluis, Lamin B Cham, Albert Gris-Oliver, et al.
The Lancet. Microbe|January 21, 2023
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2Merel J Smit, Adam F Sander, Maud B P A Ariaans, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 8, 2022
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screenZaid Taha, Rozanne Arulanandam, Glib Maznyi, et al.
ACS Infectious Diseases|October 18, 2021
Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of ConcernMadalina Elena Carter-Timofte, Rozanne Arulanandam, Naziia Kurmasheva, et al.
Nature Communications|October 22, 2020
Author Correction: SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarateDavid Olagnier, Ensieh Farahani, Jacob Thyrsted, et al.
Nature Communications|October 3, 2020
SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarateDavid Olagnier, Ensieh Farahani, Jacob Thyrsted, et al.
Pageof 5